RxDoctor Payments Data

Sumit Bhatia, MD

Retina Specialist · Normal, ILNPI 1780670596

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.8% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 24.6% of the total. That places this record below the midpoint for retina specialist clinicians in IL, where the typical reported total is $2,402.

$1,488in general payments, 2019–2025

Across 58 payments — averaging $25.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$367
  • Apellis Pharmaceuticals, Inc.$271
  • Regeneron Healthcare Solutions, Inc.$222
  • Novartis$148
  • Genentech USA, Inc.$127
  • Harrow Eye, LLC$125
  • plus $229 from 5 others
$113,167in research payments, 2019–2025

Across 19 payments — averaging $5956.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$73K
  • Apellis Pharmaceuticals, Inc.$40K

What the payments were for

  • Food & beverage$1,45498%
  • Entertainment$332%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,488 in reported general payments places this provider in the 35th percentile of 70 retina specialist providers in Illinois.

See all retina specialist providers in Illinois

Medicare billing

Part B allowed, 2024
$1,170,082
Medicare patients
245
Services billed
14,236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast12$8,363
Prednisolone Acetate83$4,191
Atropine Sulfate44$1,426
Dorzolamide Hcl33$592
Ofloxacin41$325
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat12$256
Latanoprost20$149
Ketorolac Tromethamine17$128

Paid to pharmacies, not to this prescriber.

Other retina specialist in Normal

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →